Inhibition of Cdk Activity
Abnormal Proliferation
T Cell Activation and Clonal Selection
Cytotoxic T Cells-mediated Immune Response
Tumor Immunotherapy
Mitogens and the Cell Cycle
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Aug 15, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
Charlotte Bisilliat Donnet1,2, Valérie Acolty1,2, Abdulkader Azouz2,3
1Laboratory of Immunobiology, Université Libre de Bruxelles, Gosselies, Belgium.
Targeting the PHD2/HIF-1 pathway in T cells boosts antitumor immunity. Deleting PHD2 enhances CD8+ T cell function and tumor regression, offering a promising strategy for cancer immunotherapy.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: